Company: CMND
Filing Date: 2025-11-26
Form Type: F-1
Source: 0001213900-25-115501
Chunk: 17

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-26
Form: F-1
Chunk 17
---
 and from the short-swing profit liability provisions contained in Section 16 of the Exchange Act. As a foreign
private issuer, we are also not subject to the requirements of Regulation FD (Fair Disclosure) promulgated under the Exchange Act. In
addition, as a foreign private issuer, we are permitted, and follow certain home country corporate governance practices instead of those
otherwise required under the listing rules of Nasdaq for domestic U.S. issuers. These exemptions and leniencies reduce the frequency and
scope of information and protections available to you in comparison to those applicable to a U.S. domestic reporting companies.

We may take advantage of these exemptions until
such time as we are no longer a foreign private issuer. We would cease to be a foreign private issuer at such time as more than 50% of
our outstanding voting securities are held by U.S. residents and any of the following three circumstances applies: (i) the majority of
our executive officers or directors are U.S. citizens or residents; (ii) more than 50% of our assets are located in the United States;
or (iii) our business is administered principally in the United States.

Both foreign private issuers and emerging growth
companies are also exempt from certain more stringent executive compensation disclosure rules. Thus, even if we no longer qualify as an
emerging growth company, but remain a foreign private issuer, we will continue to be exempt from the more stringent compensation disclosures
required of companies that are neither an emerging growth company nor a foreign private issuer.

<div align='center'>6</div>

THE OFFERING

| Common shares currently issued and outstanding                                                                       |     | 33,181,024 common shares                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Common Shares offered by the selling shareholders                                                                    |     | Up to an aggregate of 5,781,250 common shares                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Common Shares to be issued and outstanding after this offering (assuming exercise of the January 2024 PIPE Warrants) |     | 38,962,274 common shares (assuming exercise of the January 2024 PIPE Warrants)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Use of proceeds                                                                                                      |     | We will not receive any proceeds from the sale of the common shares by the selling shareholder. All net proceeds from the sale of the common shares covered by this prospectus will go to the selling shareholder. However, we may receive the proceeds from the exercise of any Additional Warrant Shares underlying the January 2024 PIPE Warrants if the